Skip to main content

By Biocat

Multinational corporation Amgen has named Dr. Roland Wandeler the new general manager of Barcelona-based Amgen Iberia (Spain and Portugal). Wandeler takes over for Dr. Jordi Martí , who has worked at the biotechnology subsidiary since it was created, first as sales manager and then as general manager.

Roland Wandeler, born in Switzerland to a Spanish mother, has held various executive positions in the company: director of the Osteoporosis Business Unit in Germany (2010-2012), director of National Osteoporosis Sales in Germany (2010), director of Regional Oncology and Hematology Sales (2009), Sales & Marketing Effectiveness Manager in Germany (2007-2008) and Strategic Planning Manager in Switzerland (2006-2007). Before joining Amgen, he worked for the Boston Consulting Group in Zurich and Los Angeles. He holds a Masters in Chemical Engineering and a PhD in Technical Sciences from the Swiss Federal Institute of Technology (ETH).

“Iberia is a key market for Amgen and one of the most important in Europe, not only for commercial reasons but also due to the significance of clinical research here and the quality of both professionals and centers”, explained Wandeler. "I’m sure that we will successfully weather the complicated situation the industry is currently experiencing and be able to anticipate new business needs, thanks to our innovation-based policy and access to innovative drugs.”

Amgen was founded in California in 1980. They began activity in Spain in 1990 and in Portugal in 1993. Their Barcelona headquarters currently employs 250 workers. The company specializes in the discovery, production and marketing of human therapies for serious diseases, based on breakthroughs in cell and molecular biology. Their main lines of research focus on oncology, hematology, nephrology, inflammatory diseases, metabolism and bone diseases.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.